- Home
- GLTO vs NINE Comparison
GLTO vs NINE Comparison
Compare GLTO & NINE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- NINE
- Stock Information
- Founded
- GLTO 2011
- NINE 2011
- Country
- GLTO Denmark
- NINE United States
- Employees
- GLTO N/A
- NINE N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- NINE Oilfield Services/Equipment
- Sector
- GLTO Health Care
- NINE Energy
- Exchange
- GLTO Nasdaq
- NINE Nasdaq
- Market Cap
- GLTO 23.7M
- NINE 27.5M
- IPO Year
- GLTO 2020
- NINE 2018
- Fundamental
- Price
- GLTO $16.82
- NINE $0.45
- Analyst Decision
- GLTO
- NINE
- Analyst Count
- GLTO 0
- NINE 0
- Target Price
- GLTO N/A
- NINE N/A
- AVG Volume (30 Days)
- GLTO 3.4M
- NINE 1.9M
- Earning Date
- GLTO 11-06-2025
- NINE 10-30-2025
- Dividend Yield
- GLTO N/A
- NINE N/A
- EPS Growth
- GLTO N/A
- NINE N/A
- EPS
- GLTO N/A
- NINE N/A
- Revenue
- GLTO N/A
- NINE $571,171,000.00
- Revenue This Year
- GLTO N/A
- NINE $4.56
- Revenue Next Year
- GLTO N/A
- NINE $1.41
- P/E Ratio
- GLTO N/A
- NINE N/A
- Revenue Growth
- GLTO N/A
- NINE 2.59
- 52 Week Low
- GLTO $2.01
- NINE $0.37
- 52 Week High
- GLTO $33.60
- NINE $1.87
- Technical
- Relative Strength Index (RSI)
- GLTO 55.60
- NINE 44.73
- Support Level
- GLTO $15.76
- NINE $0.37
- Resistance Level
- GLTO $29.03
- NINE $0.44
- Average True Range (ATR)
- GLTO 4.83
- NINE 0.04
- MACD
- GLTO -0.52
- NINE 0.00
- Stochastic Oscillator
- GLTO 43.02
- NINE 57.10
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About NINE Nine Energy Service Inc.
Nine Energy Service Inc is a North American onshore completion and production services provider. It targets unconventional oil and gas resource development. It operates in one segment, Completion Solutions. The Completion Solutions segment offers cementing services; completion tools, including liner hangers and accessories, frac sleeves, fully composite frac plugs, and specialty open hole float equipment and centralizers and other services. It operates in the U.S, Canada, and other countries where majority of the revenue is generated from the United States.